Does Smoldering Myeloma Always Progress?

Smoldering myeloma does not always progress to active multiple myeloma. Long-term studies show that roughly a quarter of patients remain progression-free at 15 years, and after the first decade the annual risk of progression drops to about 1%, which is comparable to a much milder precursor condition. But the overall picture is far from reassuring for everyone: the progression rate runs about 10% per year during the first five years, and the majority of patients will eventually develop symptomatic disease. What separates those who progress quickly from those who never do is the subject of intense research and increasingly practical risk-stratification tools.

How the Risk of Progression Changes Over Time

The landmark natural history data come from a study at the Mayo Clinic that followed 276 patients over more than 2,000 cumulative person-years. In that cohort, symptomatic multiple myeloma or a related condition developed in about 59% of patients. The annual risk was roughly 10% per year for the first five years, dropped to about 3% per year for the next five, and fell to around 1% per year after that. The cumulative probability of progression reached 73% at 15 years.¹ A European analysis reported very similar figures: a median time to progression of 4.8 years, with cumulative rates of 51% at 5 years, 66% at 10 years, and 73% at 15 years.²

That declining curve matters. It tells you that smoldering myeloma is not a single condition with a uniform countdown. The patients who are going to progress quickly tend to do so within the first few years. Those who make it through a decade without progression have a disease that behaves more like the even milder precursor known as MGUS (monoclonal gammopathy of undetermined significance), which carries only about a 1% annual risk. In fact, about a third of smoldering myeloma patients remain progression-free at 10 years and beyond.³

What Separates High-Risk From Low-Risk Patients

Not all smoldering myeloma carries the same threat, and risk stratification has become central to deciding who gets watched and who might benefit from early treatment. The most widely used scoring system, sometimes called the Mayo 2018 or “2/20/20” model, uses three laboratory values measured at diagnosis: the ratio of involved to uninvolved free light chains in the blood (above 20), the level of monoclonal protein (above 2 g/dL), and the percentage of plasma cells in the bone marrow (above 20%). Patients with none of these risk factors are classified as low risk, one factor puts them at intermediate risk, and two or more at high risk.⁴

The practical difference is dramatic. In the original validation of this model, median time to progression was about 110 months (over nine years) for low-risk patients, 68 months for intermediate-risk patients, and just 29 months for high-risk patients.⁵ That means a high-risk patient at diagnosis has roughly a coin-flip chance of progressing within two and a half years, while a low-risk patient may go a decade or more without any trouble.

Why the Definition Keeps Shifting

Part of the reason smoldering myeloma’s natural history looks the way it does is that the boundaries of the diagnosis have moved. Smoldering myeloma is defined by having a meaningful burden of abnormal plasma cells or monoclonal protein but no evidence of organ damage. MGUS sits below it, with lower levels of both markers.⁶

In 2014, the International Myeloma Working Group carved out a subset of what had previously been called high-risk smoldering myeloma and reclassified it as active myeloma requiring treatment. Patients meeting any one of three biomarker thresholds — 60% or more plasma cells in the bone marrow, a free light chain ratio of 100 or higher, or more than one focal bone lesion on MRI — were moved into the multiple myeloma category even without symptoms, under the rationale that their risk of progression within two years was so high that watching and waiting was no longer appropriate.⁷ This redrawing of the line improved the overall prognosis of the remaining smoldering myeloma population, because the fastest progressors were removed from the group. It also means that older studies, which included these ultra-high-risk patients, likely overstate the progression rate for patients diagnosed under current criteria.

Tracking Whether the Disease Is Evolving

A snapshot of risk factors at diagnosis gives useful information, but it does not tell you whether the disease is actually on the move. Researchers have found that changes in blood markers during the first year after diagnosis add substantial predictive power. In a recent study, patients whose monoclonal protein level climbed by 0.4 g/dL or more during the first year had a median time to progression of just 18 months, compared with 130 months for those without rising markers. Similarly, those whose free light chain ratio jumped by 40% or more progressed in a median of 41 months versus 201 months for those with stable ratios.⁸

What makes this especially useful is the combination with baseline risk. Patients who started out high-risk and then showed rising markers had two-year and five-year progression rates of 41% and 83%, respectively. At the other extreme, low-risk patients with stable markers had a five-year progression rate of just 8%, essentially behaving like MGUS.⁸ This dynamic approach is a meaningful advance because it turns the first year of observation into a live test rather than a passive wait.

Circulating Tumor Cells as an Early Warning

Another promising tool is measuring circulating plasma cells — abnormal plasma cells that have escaped the bone marrow and entered the bloodstream. Patients with elevated levels above a threshold of about 0.015% had a median time to progression of just 17 months, compared with a median that was not even reached (meaning most had not progressed) in those below the threshold. The circulating cell count was so informative that in a multivariate analysis it rendered the bone marrow plasma cell percentage statistically insignificant as an independent predictor.⁹ Earlier work using different counting methods found similarly stark differences: patients with high circulating plasma cells had a 71% progression rate within two years, versus 24% for those without.¹⁰

These blood-based tests are attractive because they can be repeated easily and do not require a bone marrow biopsy. They are not yet standard in routine clinical practice, but they are increasingly being incorporated into clinical trials and may eventually complement or even improve upon traditional scoring systems.

What Genetics Reveal About Progression Speed

Certain chromosomal abnormalities detected in the abnormal plasma cells can significantly alter the timeline. The translocation t(4;14), which rearranges chromosomes 4 and 14, is particularly aggressive. Patients carrying t(4;14) had a median time to progression of 28 months, compared with 55 months for those with the more favorable t(11;14). Deletion of a portion of chromosome 17 (del17p) was even faster, with a median time to progression of about 24 months.¹¹ More recent genomic profiling has confirmed that mutations in specific genes (DIS3, FAM46C, and FGFR3) and structural changes like gains in chromosome 1q are enriched in high-risk smoldering myeloma and may predict resistance to early treatment.¹²

An interesting insight from genomic studies is that progression from smoldering to active myeloma does not typically involve the sudden appearance of a completely new malignant clone. Instead, the subclonal populations that eventually drive active disease are usually already present at the smoldering stage. Progression involves subtle shifts in the balance of these existing subclones rather than the birth of a new one.¹³ This suggests the disease’s trajectory may be largely set early on, and the challenge is reading the signals accurately enough to predict which patients carry those dangerous subclones.

The Immune System’s Role in Holding Disease in Check

Why some patients with biologically concerning features still do not progress for years likely has a lot to do with their immune system. Research on the bone marrow environment in smoldering myeloma has shown that these patients often have upregulated immune surveillance compared with both MGUS and active myeloma. Their cytotoxic immune cells are more active — but sometimes that activation comes paired with exhaustion markers, particularly immune checkpoint molecules that essentially put the brakes on those same cells.¹⁴

In one gene expression study of 28 smoldering myeloma patients, those whose immune cells showed high activation but also high expression of inhibitory checkpoints — an exhausted immune profile — progressed faster than those whose immune environment was lower in both activation and exhaustion. The patients who stayed progression-free longer had a less inflamed but also less suppressed immune landscape.¹⁵ This is a counterintuitive finding: more immune activity is not always better if it is accompanied by more immune suppression. It also opens the door to checkpoint-based therapies. Early data on checkpoint inhibitor use in smoldering myeloma suggest that patients with higher baseline levels of exhausted T cells may actually be better responders, because those cells can be “released” by the therapy.¹⁶

When Imaging Changes the Diagnosis

Advanced imaging has quietly changed the landscape of smoldering myeloma by catching bone involvement that conventional tests miss. In a prospective trial combining PET-CT with whole-body MRI in high-risk smoldering myeloma patients, MRI identified bone lesions in about 12% of cases that PET-CT missed entirely, leading those patients to be reclassified as having active myeloma requiring treatment. Among the remaining confirmed smoldering myeloma patients, roughly 22% showed subtle bone marrow changes on MRI that could carry prognostic significance even though they did not meet the threshold for reclassification.¹⁷

Hybrid PET/MRI imaging has shown similar results in broader myeloma populations, detecting focal lesions in about 22% of smoldering myeloma patients and significantly altering clinical management.¹⁸ The practical implication is that some patients diagnosed with smoldering myeloma on conventional imaging are actually harboring early bone disease that warrants treatment. As advanced imaging becomes more available, the smoldering myeloma population will continue to shrink at the high-risk end, further improving the prognosis of the patients who remain in the category.

Early Treatment Versus Observation

For decades, the standard approach to smoldering myeloma was to watch and wait, treating only when organ damage appeared. That paradigm is shifting, particularly for high-risk patients. The pivotal Spanish trial randomized high-risk smoldering myeloma patients to either lenalidomide plus dexamethasone or observation. After an initial follow-up of about 40 months, the treatment group had a dramatically longer time before progression compared with the observation group, with a median that had not yet been reached versus just 21 months. The three-year survival rate was also higher in the treatment arm (94% versus 80%).¹⁹

With over 12 years of median follow-up, that benefit has held. The median time to progression in the observation arm was 2.1 years, compared with 9.5 years in the treatment arm, confirming a sustained advantage in both delaying progression and improving survival.²⁰ An independent North American trial confirmed that lenalidomide significantly delays progression and end-organ damage in smoldering myeloma.²¹

Monoclonal antibody therapy is also being explored. Daratumumab, widely used in active myeloma, showed promising results in a randomized trial for intermediate- and high-risk smoldering myeloma patients, with the most intensive dosing schedule producing the lowest rates of progression.²² A Cochrane review of the evidence assessed that early daratumumab may reduce the risk of progression or death by roughly half compared with active monitoring, though the certainty of the evidence was graded as low.²³

The Intensity Debate

If early treatment works, the natural question is how aggressively to treat. Some researchers have tested full myeloma-level regimens on the theory that hitting the disease hard enough at the smoldering stage could eliminate it before it fully transforms. One trial gave high-risk patients the combination of carfilzomib, lenalidomide, and dexamethasone followed by stem cell transplant and maintenance — an approach normally reserved for symptomatic myeloma. After about six years of follow-up, 31% of patients had sustained undetectable minimal residual disease four years after transplant, a finding the investigators described as encouraging for potential cure.²⁴

However, a systematic review comparing different intensity levels found something sobering: deeper responses came with more intensive treatment, but survival did not proportionally improve. Moderate- and high-intensity regimens produced similar rates of undetectable residual disease and similar overall survival. Even low-intensity approaches delayed progression and improved survival in high-risk patients.²⁵ This means the field has not settled on the right approach: more treatment clearly suppresses the disease more aggressively, but whether that translates into longer lives — as opposed to just longer remissions — remains an open question.

Racial Differences in Progression Risk

Multiple myeloma is about twice as common in Black Americans as in white Americans, and the precursor conditions leading to it are also more frequent. But an intriguing finding from recent research is that among patients already diagnosed with smoldering myeloma, Black patients may actually progress more slowly. In a study at the Mayo Clinic, African American patients had a significantly longer median time to progression (9.7 years versus 6.2 years) and lower two-year (about 13% versus 20%) and five-year (34% versus 45%) progression rates than white patients. This difference persisted even after adjusting for age, sex, and the standard laboratory risk factors.²⁶

This finding is still being investigated and the study is a single-center analysis, so it needs confirmation. But if it holds, it has real implications for how risk models are applied across populations. Standard scoring systems were developed and validated predominantly in white patient cohorts, and they may overestimate risk in Black patients. That overestimation could push patients toward unnecessary early treatment or heightened anxiety about progression that does not match their actual trajectory.

Living With the Uncertainty

Being told you have a condition that is not cancer yet but might become cancer creates a psychological burden that is easy to underestimate. Research on the emotional toll of smoldering myeloma and MGUS found that about 19% of patients experienced clinically significant anxiety, and roughly a third had a history of psychiatric disorders.²⁷ The anxiety rates were actually slightly lower in smoldering myeloma patients than in MGUS patients in that study, possibly because smoldering myeloma patients tend to receive more structured follow-up and clearer communication about their monitoring plan.

If you have been diagnosed with smoldering myeloma, the most useful thing you can do psychologically is understand that your individual risk profile matters far more than the average statistics. A low-risk patient with stable blood markers over the first year has a fundamentally different outlook than a high-risk patient with rising markers, even though both carry the same diagnosis on paper. Ask your hematologist specifically about your risk category and whether your markers are evolving, because those two pieces of information together give a much clearer picture than the diagnostic label alone.